Jul. 17 Pre-market Movers Board: BYND Cannasoft slumps 47% premarket after reporting a proposed underwritten offering

Seize the market opportunities with us at 8:45 every morning, and don't forget to check our ‘Lunchtime Movers Board’ at 12:00.

Premarket Gainers: BridgeBio, Acumen, argenx, PainReform, Activision

BBIO:

BridgeBio Pharma surges 65% after saying it would share results from the latest phase of its transthyretin amyloid cardiomyopathy heart disease study.

ABOS:

Acumen Pharmaceuticals climbs 45% premarket after presenting Positive Topline results from first-in-human Phase 1 study of ACU193.

ARGX:

argenx climbs 26% premarket after reporting Positive Topline data from adhere study of Vyvgart Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy.

PRFX:

PainReform surges 17% premarket after pricing  $1.5 million securities offering.

ATVI:

Activision Blizzard spikes 4% premarket after Microsoft reached a 10-year agreement to keep "Call of Duty" games on PlayStation consoles after the U.S.

Premarket Losers: BYND, Minerva, Meten, Baosheng, Frequency

BCAN:

BYND Cannasoft Enterprises slumps 47% premarket after reporting a proposed underwritten public offering.

UTRS:

Minerva Surgical sinks 12% premarket after climbing 22% last Friday.

METX:

Meten Holding drops 11% premarket after the Co. to issue to the sellers ordinary shares of the company.

BAOS: 

Baosheng Media Group slides 9% premarket after jump 28% at previous close.

FREQ: 

Frequency shares down 8% premarket after surging 77% last trading session.

$BBIO(BBIO)$ABOS(ABOS)$PRFX(PRFX)$ARGX(ARGX)$ATVI(ATVI)$BCAN(BCAN)$UTRS(UTRS)$METX(METX)$BAOS(BAOS)$FREQ(FREQ)